Lactobacillus fermentum Ess-1 with unique growth inhibition of vulvo-vaginal candidiasis pathogens.
The aim of this study was to characterize human isolates of Lactobacillus species for their capacity to interfere with the growth of different strains of Candida species in vitro in the search for a potential probiotic. Growth inhibition of Candida species was screened using an agar-overlay method. Inhibiting strains were selected to assay the effect of a cell-free Lactobacillus culture filtrate (LCF) on the growth of isolates of Candida albicans and Candida glabrata. A total of 126 human Lactobacillus isolates was investigated. Eighteen isolates significantly inhibited the growth of C. albicans on agar. The LCF of one of these strains showed strong inhibition of both C. albicans and C. glabrata. This strain was genetically identified as Lactobacillus fermentum and designated L. fermentum Ess-1. Further tests to evaluate the probiotic potential of this strain indicated that L. fermentum Ess-1 strain is a promising probiotic for use in clinical trials to treat and prevent vulvo-vaginal candidiasis.
Rönnqvist
Daniel
D
Department of Clinical Bacteriology, Umeå University, Umeå, Sweden.
Forsgren-Brusk
Ulla
U
SCA Hygiene Products AB, Gothenburg, Sweden.
Husmark
Ulrika
U
SCA Hygiene Products AB, Gothenburg, Sweden.
Grahn-Håkansson
Eva
E
Essum AB, Umeå, Sweden.
D000328:Adult; D000898:Antibiosis; D002176:Candida albicans / Q000254:growth & development* / Q000302:isolation & purification; D041221:Candida glabrata / Q000254:growth & development* / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000382:microbiology*; D005243:Feces / Q000382:microbiology; D005260:Female; D005546:Forehead / Q000382:microbiology; D006801:Humans; D007231:Infant, Newborn; D052197:Limosilactobacillus fermentum / Q000302:isolation & purification / Q000502:physiology*; D010614:Pharynx / Q000382:microbiology; D014070:Tooth / Q000382:microbiology; D014621:Vagina / Q000382:microbiology